Researchers in the U.K. tested AstraZeneca’s PARP inhibitor Lynparza and found it can penetrate the blood-brain barrier and invade glioblastoma tumors.

Broad Institute scientists have created an RNA-editing method that makes reversible changes to DNA possible.

A synthetic DNA vaccine developed by the Wistar Institute and Penn scientists, with support from Inovio and GeneOne, shows promise in human trials.

UC Berkeley scientists are using a new CRISPR delivery system to more safely correct the mutated dystrophin gene in mouse models of DMD.

This past week saw new discoveries in treating heart failure, targeting Zika and dengue with one drug and inhibiting a cancer-promoting enzyme.

A new test quickly shows if an antibiotic fights a given infection, which can reduce improperly prescribed antibiotics.

With some tweaks, a gene therapy delivered to the liver could become a new treatment for multiple sclerosis.

Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV infection in healthy people.